MEM may get strong exposure
Donald Trump recently referred to himself as the "fertilization president" during a Women's History Month event at the White House. He made the remark while discussing his administration's efforts to expand access to in vitro fertilization (IVF) treatments. Trump has also previously called himself the "father of IVF" during his 2024 campaign
Here are some of the latest updates on IVF in the U.S.:
- Trump's Baby Boom Push: The Trump administration is advancing proposals to address America's declining birth rate, including IVF subsidies, a $5,000 baby bonus, and expanded child tax credits.
- CDC IVF Team Cut: The Centers for Disease Control and Prevention's Assisted Reproductive Technology Surveillance team was eliminated, raising concerns about tracking IVF success rates.
- Tennessee IVF Protections: A bill codifying protections for birth control and IVF in Tennessee has faced opposition from Republican lawmakers urging Governor Bill Lee to veto it.
- Trump's Executive Order on IVF: President Trump signed an executive order aimed at reducing the cost of IVF and expanding access to fertility treatments
Will this vitro deal help Memphasys
Yes, the Vitrolife distribution agreement could be beneficial for Memphasys (ASX: MEM). The deal expands Memphasys' reach into Canada and New Zealand, allowing Vitrolife to sell and distribute the Felix™ System, a sperm separation technology used in IVF
This partnership strengthens Memphasys' commercial presence and could boost revenue by tapping into new markets. Additionally, Memphasys has already established a footprint in Canada through Key Opinion Leader (KOL) networks, which may help drive adoption
Memphasys has signed exclusive distribution agreements with Vitrolife for Japan, Canada, and New Zealand, but there is no official announcement regarding the U.S. market yet. The company has been working on regulatory submissions, which could pave the way for future entry into markets like the U.S.
If Memphasys (ASX:MEM) expands Felix™ into the U.S. market, whether through Vitrolife or other distributors, it could significantly boost its visibility and potential sales. The U.S. fertility sector is one of the world's largest, and with Trump’s push for expanded IVF access, there's a growing opportunity for innovative technologies like Felix™.
Memphasys has already secured distribution agreements for Felix™ in Japan, Canada, and New Zealand, but no official confirmation on U.S. distribution has been made. If that changes, it could be a pivotal moment for the company's global growth strategy.
Maybe USA distribution agreement announcement imminent 
Here
Vitrolife is a major global player in the fertility sector, known for its advanced IVF-related medical devices and genetic testing services. If Vitrolife were to distribute the Felix™ Sperm Separation System from Memphasys (ASX:MEM) in the U.S., it could be a strong commercial move.
That said, successful market entry depends on several factors:
- Regulatory approvals: Felix™ would need clearance from U.S. health authorities for widespread clinical use.
- Competitive landscape: Other fertility technologies, including traditional sperm separation methods, will still influence market adoption.
- Vitrolife’s priorities: While Vitrolife has global distribution agreements with Memphasys for Japan, Canada, and New Zealand,
- A U.S. deal hasn’t been publicly announced. YET???
(20min delay)